Syneos Health
Syneos Health, a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself as a key player in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to navigate the complexities of drug development more effectively. Their innovative approach and commitment to delivering results have positioned them as a trusted partner for pharmaceutical and biotechnology companies. With a strong market presence, Syneos Health has achieved notable milestones, including recognition for its comprehensive service offerings and a focus on patient-centric solutions, making it a preferred choice in the competitive landscape of biopharmaceutical services.
DitchCarbon Score
How does Syneos Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Syneos Health's score of 65 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Syneos Health's reported carbon emissions
In 2024, Syneos Health reported total carbon emissions of approximately 16,500,000 kg CO2e for Scope 1, 5,116,000 kg CO2e for Scope 2 (market-based), and significant Scope 3 emissions, including 172,500,000 kg CO2e from purchased goods and services and 36,888,000 kg CO2e from business travel. In 2023, the figures were slightly lower, with Scope 1 emissions at about 16,298,000 kg CO2e and Scope 2 emissions at 9,704,000 kg CO2e (market-based). Syneos Health has set ambitious climate commitments, including a target to reduce Scope 1 and 2 emissions by 42% by 2030 from a 2023 baseline. Additionally, the company aims to cut Scope 3 emissions from purchased goods and services and business travel by 25% within the same timeframe. These targets are aligned with the Science Based Targets initiative (SBTi) and are part of their broader commitment to achieving net zero carbon emissions by 2040, as outlined in The Climate Pledge, which they signed in December 2021. Overall, Syneos Health is actively working towards significant reductions in their carbon footprint across all scopes, demonstrating a strong commitment to sustainability in the pharmaceutical and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 16,298,000 | 00,000,000 |
| Scope 2 | 9,704,000 | 0,000,000 |
| Scope 3 | 261,804,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syneos Health is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
